Valeant Has Increased The Cost Of Salix Acquisition
Valeant increased the cost of the offer for the acquisition of Salix Pharmaceuticals to 10.96 billion dollars. Earlier, the Canadian company agreed to buy Salix for 10.1 billion dollars.
Th value of the transaction was increased due to competitive offers made by Endo, who declared their readiness to pay 10,93 billion for Salix's shares.
Salix Pharmaceuticals Board of Directors agreed to the last Valeant's offer, according to which the holders of drugmaker securities will receive 173 dollars per share. Last month, it was about 158 dollars per Salix security.
Salix specializes in designing and manufacturing the drugs against infectious diseases of the gastrointestinal tract. Its portfolio includes 22 drug items.
- Acorda Acquires Civitas Together With The Rights To A Promising Antiparkinsonian Agent
- Abbott Can Acquire Russian Veropharm By The End Of The Year
- Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion